c3 inhibitor amy 101  (MedChemExpress)

Journal: Blood Vessels, Thrombosis & Hemostasis

Article Title: A second generation of C3 humanized rats for preclinical evaluation of human C3 inhibitors

doi: 10.1016/j.bvth.2026.100138

Figure Lengend Snippet: C3 inhibitor AMY-101 inhibits the alternative but not classical pathway complement-mediated hemolysis in the second-generation hC3 rats in vitro. (A) The C3 inhibitor AMY-101 (0.3-20μM) was incubated with rabbit RBCs in the presence of 80% WT rat serum, or second-generation hC3 rat serum in Mg 2+ -EGTA buffer at 37°C for 30 minutes, then hemolysis was quantitated, showing that AMY-101 almost completely inhibited the second-generation hC3 rat alternative pathway-mediated hemolysis at a concentration as low as 2.5μM while did not affect the WT rat alternative pathway-mediated hemolysis at a concentration as high as 20μM. (B) The C3 inhibitor AMY-101 (0.3-10μM) were incubated with antibody-sensitized sheep RBCs in the presence of 10% second-generation hC3 rat serum in GVB ++ buffer at 37°C for 30 minutes, then hemolysis was quantitated, showing that AMY-101 did not have any effect on the second-generation hC3 rat classical pathway-mediated hemolysis at a concentration as high as 10μM. 2nd gen, second generation.

Article Snippet: To evaluate the inhibitory effect of the C3 inhibitor AMY-101 (MedChemExpress, catalog no. HY-P1717) on alternative pathway activation in the new hC3 rat serum, 80% hC3 rat serum or WT rat serum was incubated with rabbit RBCs in the presence of 0.3 to 20μM AMY-101 in Mg 2+ -EGTA GVB buffer at 37°C for 30 minutes.

Techniques: In Vitro, Incubation, Concentration Assay

Journal: Blood Vessels, Thrombosis & Hemostasis

Article Title: A second generation of C3 humanized rats for preclinical evaluation of human C3 inhibitors

doi: 10.1016/j.bvth.2026.100138

Figure Lengend Snippet: AMY-101 significantly prolongs the survival of rabbit RBCs in the second-generation hC3 rats in vivo. Rabbit RBCs (2 × 10 9 ), labeled with Vybrant Dil dye, were IV injected into second-generation hC3 rats in the presence or absence of 1 mg/kg AMY-101. Blood samples were collected at 0.5, 1, 2, 5, 10, 20, and 30 minutes after injection and the survived circulating fluorescence-labeled rabbit RBCs were quantitated by flow cytometry. (A) Representative flow cytometry data showing the circulating rabbit RBCs without and with AMY-101 treatment at different time points. (B) Summary of the rabbit RBC (ER) survival data over the 0.5-30 minute course in the second-generation hC3 rats with or without AMY-101 treatment. Two-way analysis of variance, ∗∗∗∗ P < .001; ∗∗∗ P < .001; ∗ P < .05. FSC, forward scatter; ER, rabbit erythrocytes; PE, phycoerythrin.

Article Snippet: To evaluate the inhibitory effect of the C3 inhibitor AMY-101 (MedChemExpress, catalog no. HY-P1717) on alternative pathway activation in the new hC3 rat serum, 80% hC3 rat serum or WT rat serum was incubated with rabbit RBCs in the presence of 0.3 to 20μM AMY-101 in Mg 2+ -EGTA GVB buffer at 37°C for 30 minutes.

Techniques: In Vivo, Labeling, Injection, Fluorescence, Flow Cytometry

Journal: Blood Vessels, Thrombosis & Hemostasis

Article Title: A second generation of C3 humanized rats for preclinical evaluation of human C3 inhibitors

doi: 10.1016/j.bvth.2026.100138

Figure Lengend Snippet: Anti-rabbit RBC IgM/IgG antibodies exist in the rats, and the AMY-101–treated rats exhibit classical pathway hemolytic activities comparable to the mock-treated rats. Rabbit RBCs were incubated with second-generation hC3 rat serum (+EDTA) for 30 minutes on ice, then washed. The surface binding rat IgM (A) and IgG (B) on the rabbit RBCs were detected by flow cytometry. To evaluate classical pathway hemolytic activity, antibody-sensitized sheep RBCs were incubated with 10% serum from the AMY-101 or mock-treated second-generation hC3 rats in the presence of Ca 2+ and Mg 2+ for 20 minutes, and then hemolysis was quantitated (C). (D) In a different experiment, additional AMY-101 (0-10μM) was added into the AMY-101–treated rat serum, and the classical pathway hemolytic activities were measured again.

Article Snippet: To evaluate the inhibitory effect of the C3 inhibitor AMY-101 (MedChemExpress, catalog no. HY-P1717) on alternative pathway activation in the new hC3 rat serum, 80% hC3 rat serum or WT rat serum was incubated with rabbit RBCs in the presence of 0.3 to 20μM AMY-101 in Mg 2+ -EGTA GVB buffer at 37°C for 30 minutes.

Techniques: Incubation, Binding Assay, Flow Cytometry, Activity Assay